Paradigm Biocapital Advisors LP
Q2 2022 13F-HR Holdings
Net value change ($000)
+123,355
(32.6%)
New positions
5
Sold out positions
7
Turnover %
30.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Mirati Therapeutics, Inc. | 36,215 | 447.7% |
| ARGX | 33,651 | NEW |
| UTHR | 24,855 | 183.2% |
| INCY | 23,625 | 126.9% |
| LEGN | 23,598 | 78.1% |
| Sierra Oncology, Inc. | 19,343 | 78.2% |
| BCYC | 17,594 | NEW |
| Global Blood Therapeutics, Inc. | 12,695 | 37.9% |
| IMCR | 9,975 | 66.8% |
| TGTX | 8,350 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| IVERIC bio, Inc. | -15,322 | -100.0% |
| IOVA | -15,109 | -100.0% |
| Horizon Therapeutics Public Ltd Co | -14,334 | -100.0% |
| ZNTL | -13,269 | -100.0% |
| CCCC | -11,566 | -95.4% |
| ARVN | -11,289 | -34.1% |
| PRTA | -9,799 | -100.0% |
| KYMR | -9,608 | -100.0% |
| VRDN | -8,107 | -34.9% |
| OYST | -5,724 | -49.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|